ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "cancer treatments and myositis"

  • Abstract Number: 2288 • 2018 ACR/ARHP Annual Meeting

    Preexisting Anti-Acetylcholine Receptor Autoantibodies and B Cell Lymphopenia Are Associated with the Development of Myositis in Thymoma Patients Treated with Avelumab, an Immune Checkpoint Inhibitor Targeting Programmed Death-Ligand 1

    Andrew Mammen1, Arun Rajan2, Katherine Pak1, Tanya Lehky3, Livia Casciola-Rosen4, Renee Donahue2, Lauren Lepone2, Anastasia Zekeridou5, Sean Pittock5, Raffit Hassan2, Jeffrey Schlom2 and James Gulley2, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2NCI, NIH, Bethesda, MD, 3NINDS, NIH, Bethesda, MD, 4Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 5Neurology, Mayo Clinic, Rochester, MN

    Background/Purpose: Immune checkpoint inhibitors (ICIs) enhance the immune response against tumors but may also trigger immune-related adverse events (IRAEs). Myositis following receipt of ICIs is…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences